Steven Bardy leaves New Zealand FMA amid leadership turnover

Exterior of a government office building illustrating the leadership changes at New Zealand's Financial Markets Authority
Photo by Brett Sayles on Pexels

Steven Bardy is leaving the board of New Zealand's Financial Markets Authority (FMA) this week. His resignation takes effect on Friday, and the regulator has not identified a replacement.

He joined the board in 2022 and became deputy chairman in January. Before that, Bardy held a senior executive role at the Australian Securities and Investments Commission (ASIC) and was the first chairman of the Assessment Committee of the International Organization of Securities Commissions (IOSCO).

The departure follows two other senior exits. Craig Stobo resigned as chairman in May, while chief executive Samantha Barrass left on September 3. Barrass had led the FMA since January 2022. Alastair Hercus is serving as acting chief executive. Board chairman James Miller said Bardy had taken on the acting chair role while the regulator was going through a difficult period.

The inquiries behind earlier exits

Bardy had chaired the board on an interim basis from December 2025 until Miller took over on August 6 for a five-year term. In a letter sent to Commerce and Consumer Affairs Minister Cameron Brewer on Thursday, Bardy said he had discussed leaving with Miller for several months.

He had chosen to stay until after voters went to the polls on November 7. The letter said he looked forward "to seeing the benefits of the reset he is overseeing."

Stobo had stepped aside in December 2025 after the Ministry of Business, Innovation and Employment (MBIE) commissioned an independent inquiry into him. Wendy Aldred KC led the review, which concluded that some of Stobo's public remarks did not satisfy the political neutrality expected from the head of an independent Crown entity. He resigned in May.

The FMA's workplace conduct and culture review is still under way. Barrass went on leave in late July after the board raised concerns about internal culture. MBIE appointed Kristy McDonald KC on August 4 to examine those matters. Barrass's term was due to finish in January 2027, but she had already said she would not renew it. The board ended her suspension, and its employment inquiry into her was incorporated into MBIE's process.

The inquiry has not issued findings, and MBIE has not set a completion date. Barrass said she would leave the matter to the investigation.

FMA oversight spans several markets

The board changes affect a regulator that licenses firms offering CFDs and other derivatives to New Zealand clients. In 2024, the FMA cancelled Rockfort Markets' derivatives issuer licence after a five-year dispute. It also took part in an April operation against unlawful finfluencers with 16 other regulators, contacting 14 social media promoters. Since July 1, the FMA has overseen consumer credit, a duty transferred from the Commerce Commission.

The leadership timeline and regulatory remit were reported by Finance Magnates. Other regulators brokers deal with have also seen leadership changes this year: Sarah Court became ASIC chairwoman on June 1 after Joe Longo declined to seek another term, while Carlo Comporti replaced Verena Ross at the European Securities and Markets Authority (ESMA) on November 1. At the FMA, the chairman, chief executive and deputy chairman roles have all changed hands within about six months.

What this means on the desk

The source does not report a change to licensing requirements or a new timetable for firms supervised by the FMA. For brokers and derivatives providers, the immediate operational unknown is whether existing contacts and escalation routes will remain the same after Friday. The FMA has not named Bardy's successor.

Compliance and operations teams can check who will handle regulator communications on licensing and consumer credit, and whether any open submissions or supervisory work need a new board-level contact. The continuing MBIE inquiry also leaves a question about when the regulator's internal review process will reach a conclusion. No end date has been announced.